Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.994
-0.038 (-1.25%)
Jun 5, 2026, 5:36 PM CET
Oryzon Genomics Earnings Call Transcripts
Fiscal Year 2026
-
Strong clinical data for iadademstat in AML show 100% response rates and favorable safety, supporting plans for accelerated approval in high-risk subgroups. Market analysis projects over $1 billion US peak sales, with a diversified pipeline and CNS assets targeting large unmet needs.
Fiscal Year 2025
-
Key opinion leaders highlighted the urgent need for effective BPD treatments, with Vafidemstat showing rapid, significant improvements in agitation and aggression and a favorable tolerability profile. The drug’s novel mechanism and real-world trial design support its potential for approval and broader psychiatric application.